{
    "Trade/Device Name(s)": [
        "INNOVANCE Antithrombin"
    ],
    "Submitter Information": "Dade Behring Marburg GmbH A Siemens Company",
    "510(k) Number": "K081769",
    "Predicate Device Reference 510(k) Number(s)": [
        "K933125"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JBQ"
    ],
    "Summary Letter Date": "May 28, 2009",
    "Summary Letter Received Date": "March 24, 2009",
    "Submission Date": "March 23, 2009",
    "Regulation Number(s)": [
        "21 CFR 864.7060"
    ],
    "Regulation Name(s)": [
        "Antithrombin II assay"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Antithrombin"
    ],
    "Specimen Type(s)": [
        "Human citrated plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BCS System",
        "BCS XP System"
    ],
    "Method(s)/Technology(ies)": [
        "Chromogenic assay"
    ],
    "Methodologies": [
        "Automated quantitation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for INNOVANCE Antithrombin chromogenic assay for quantitation of antithrombin in human citrated plasma",
    "Indications for Use Summary": "Chromogenic assay for automated quantitation of functionally active antithrombin in human citrated plasma as an aid in diagnosis of antithrombin deficiency",
    "fda_folder": "Hematology"
}